Microbot Medical stock maintains Buy rating at H.C. Wainwright on patent win

Microbot Medical (MBOT) secured a new patent for its LIBERTY endovascular robotic system, significantly expanding its U.S. addressable market from 2.5 million to over 6 million annual procedures, prompting H.C. Wainwright to reiterate its Buy rating and $9.00 price target. With its stock surging 195% year-to-date, the company is preparing for commercialization ahead of an anticipated Q3 2025 FDA decision for LIBERTY, supported by a recent $3 million capital raise and a doubling of authorized shares. This patent grant bolsters MBOT's intellectual property and market opportunity as it approaches a pivotal regulatory milestone.

Analysis

Microbot Medical (MBOT) has received a significant catalyst with a new U.S. patent for its LIBERTY endovascular robotic system, prompting H.C. Wainwright to reiterate its Buy rating and a $9.00 price target. The patent's key feature is a modular design that more than doubles the system's total addressable market in the U.S. alone, from 2.5 million to over 6 million annual procedures. This development supports the stock's remarkable momentum, which has seen a surge of over 195% year-to-date to trade near its 52-week high of $3.38. Operationally, the company is preparing for commercialization by strengthening its balance sheet with a $3 million capital raise, appointing a new VP of Sales, and doubling its authorized common stock to 120 million shares, indicating readiness for future financing needs. However, the entire commercialization effort is contingent upon a critical binary event: the FDA's 510(k) premarket notification decision, which is not expected until the third quarter of 2025. This extended timeline introduces significant execution and regulatory risk despite the bolstered intellectual property portfolio, which now includes 12 granted patents globally.

Key Decisions for Investors

• Investors should weigh the substantial upside potential, reflected in the $9.00 analyst price target and expanding addressable market, against the high-risk, pre-revenue nature of the company.
• The primary factor to monitor is the progress toward the FDA's 510(k) decision, anticipated in Q3 2025, as this remains the single most critical catalyst and a binary risk for the stock's valuation.
• Consider the potential for future shareholder dilution, as the company recently raised capital and doubled its authorized shares to fund operations and commercial infrastructure ahead of a potential U.S. launch.